English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Numerous lines of evidence previously indicated that conserved dopamine neurotrophic factor (CDNF) has potential therapeutic value for Parkinson's disease (PD); however, this hypothesis remains controversial. In the present study, the therapeutic effects of engineered CDNF-expressing bone marrow stromal cells (CDNF-BMSCs) on dopaminergic (DA) neurons were evaluated in vivo. CDNF-BMSCs and control BMSCs were transplanted into the rat striatum and one week later, 6-hydroxydopamine (6-OHDA) was administered to induce neurotoxicity. It was discovered that intrastriatal transplantation of CDNF-BMSCs significantly reduced 6-OHDA-induced neurotoxicity in DA neurons with regard to behavioral recovery and tyrosine hydroxylase levels in the substantia nigra and striatum. These data therefore indicated that transplantation of engineered CDNF-BMSCs into the striatum may present a beneficial strategy for the treatment of PD.

molecular medicine reports

Effects of engineered conserved dopamine neurotrophic factor-expressing bone marrow stromal cells on dopaminergic neurons following 6-OHDA administrations